JP7837967B2 - 抗眩暈組成物及びその医薬組成物 - Google Patents

抗眩暈組成物及びその医薬組成物

Info

Publication number
JP7837967B2
JP7837967B2 JP2023525964A JP2023525964A JP7837967B2 JP 7837967 B2 JP7837967 B2 JP 7837967B2 JP 2023525964 A JP2023525964 A JP 2023525964A JP 2023525964 A JP2023525964 A JP 2023525964A JP 7837967 B2 JP7837967 B2 JP 7837967B2
Authority
JP
Japan
Prior art keywords
dizziness
levocloperastine
pharmaceutical composition
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023525964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506229A (ja
JP2024506229A5 (enExample
Inventor
ヴィアス，ニラヴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amneal Pharmaceuticals LLC
Original Assignee
Amneal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amneal Pharmaceuticals LLC filed Critical Amneal Pharmaceuticals LLC
Publication of JP2024506229A publication Critical patent/JP2024506229A/ja
Publication of JP2024506229A5 publication Critical patent/JP2024506229A5/ja
Application granted granted Critical
Publication of JP7837967B2 publication Critical patent/JP7837967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023525964A 2020-10-28 2021-09-10 抗眩暈組成物及びその医薬組成物 Active JP7837967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021047025 2020-10-28
IN202021047025 2020-10-28
PCT/IN2021/050886 WO2022091118A1 (en) 2020-10-28 2021-09-10 Anti-vertigo compound and pharmaceutical compositions thereof

Publications (3)

Publication Number Publication Date
JP2024506229A JP2024506229A (ja) 2024-02-13
JP2024506229A5 JP2024506229A5 (enExample) 2024-09-19
JP7837967B2 true JP7837967B2 (ja) 2026-03-31

Family

ID=81382136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525964A Active JP7837967B2 (ja) 2020-10-28 2021-09-10 抗眩暈組成物及びその医薬組成物

Country Status (7)

Country Link
US (1) US12685728B2 (enExample)
EP (1) EP4236923A4 (enExample)
JP (1) JP7837967B2 (enExample)
CN (1) CN116963737A (enExample)
AU (1) AU2021368635A1 (enExample)
CA (1) CA3200533A1 (enExample)
WO (1) WO2022091118A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385491A1 (en) 1989-03-03 1990-09-05 MAGIS FARMACEUTICI S.p.A. Optically active isomer of cloperastine possessing antitussive activity, a process for its preparation and pharmaceutical compositions which contain it
EP0894794A1 (en) 1997-07-31 1999-02-03 AESCULAPIUS FARMACEUTICI S.r.l. Optical isomers of cloperastine
JP2004269513A (ja) 2003-02-19 2004-09-30 Rohto Pharmaceut Co Ltd 固形製剤
WO2019004953A1 (en) 2017-06-29 2019-01-03 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089234A2 (en) * 2008-01-07 2009-07-16 Auspex Pharmaceuticals Substituted dibenzhydrylpiperazines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385491A1 (en) 1989-03-03 1990-09-05 MAGIS FARMACEUTICI S.p.A. Optically active isomer of cloperastine possessing antitussive activity, a process for its preparation and pharmaceutical compositions which contain it
EP0894794A1 (en) 1997-07-31 1999-02-03 AESCULAPIUS FARMACEUTICI S.r.l. Optical isomers of cloperastine
JP2004269513A (ja) 2003-02-19 2004-09-30 Rohto Pharmaceut Co Ltd 固形製剤
WO2019004953A1 (en) 2017-06-29 2019-01-03 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY

Also Published As

Publication number Publication date
CA3200533A1 (en) 2022-05-05
US12685728B2 (en) 2026-07-21
EP4236923A4 (en) 2024-09-25
WO2022091118A1 (en) 2022-05-05
AU2021368635A1 (en) 2023-06-08
EP4236923A1 (en) 2023-09-06
US20230390271A1 (en) 2023-12-07
CN116963737A (zh) 2023-10-27
JP2024506229A (ja) 2024-02-13
AU2021368635A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US20220265624A1 (en) Sustained release aminopyridine composition
ES2829279T3 (es) Forma de dosificación oral de ketamina
AU2003240719B2 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
US12016951B2 (en) Edaravone pharmaceutical composition
JPWO2010147169A1 (ja) 溶出性の改善された医薬組成物
WO2004082684A1 (en) Stable oral formulations of aminopyridines and uses thereof
JP2024506229A (ja) 抗眩暈組成物及びその医薬組成物
WO2022157808A1 (en) Synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases
US20220193043A1 (en) Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
US20240269083A1 (en) Prolonged-release pharmaceutical composition for oral administration of sultiame
KR20250015905A (ko) 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
CN117355296A (zh) 用于口服施用舒噻美的延长释放药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240123

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251006

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260318

R150 Certificate of patent or registration of utility model

Ref document number: 7837967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150